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ABSTRACT 
 
The transcription factor ZNF224 was recently identified as a proapoptotic 
factor in chronic myelogenous leukemia (CML), mediating ara-C drug- 
induced apoptosis. Most recently, we demonstrated that the fusion protein 
Bcr-Abl negatively regulates ZNF224 expression in CML, while Bcr-Abl 
inhibition by the tyrosine kinase inhibitor (TKI) Imatinib, used as first-line 
treatment in CML, triggers ZNF224 up-regulation in CML cells. 
On the other hand, Bcr-Abl via Jak2 activation increases the expression of 
c-Myc gene, which is required for Bcr-Abl oncogenic transformation in 
CML. Coherently, Bcr-Abl inhibition by Imatinib results in c-Myc 
reduction, which represents a key step for Imatinib and new generation TKIs 
responsiveness in CML. 
In this work, we demonstrated that ZNF224 is a novel transcriptional 
repressor of c-Myc oncogene in CML and coherently, hampers c-Myc 
proliferative network, reducing CML cells proliferation and DNA synthesis. 
Intriguingly, our data describe a crucial role for ZNF224 induction in 
Imatinib repression on c-Myc in CML and subsequently demonstrate that 
alterations in ZNF224 binding sites on c-Myc promoter significantly affect 
Imatinib transcriptional repression of c-Myc gene in CML cells, thus 
suggesting a potential implication of this region in Imatinib responsiveness. 
In addition, we further reveal that AG490, a potent Jak2 inhibitor, negatively 
regulate c-Myc, at least in part via ZNF224 up-regulation. 
A crucial problem linked to TKIs treatment in CML is the possibility to 
develop resistance towards these drugs. Here we demonstrate that ZNF224 
expression is lower in Imatinib-resistant CML cells and that its induction by 
Imatinib is impaired, but can be restored by AG490. Consistently, AG490 
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treatment or ZNF224 induction in Imatinib-resistant CML cells results in c-
Myc reduction and apoptosis induction. 
Moreover, enforcing ZNF224 implications in Imatinib responsiveness, we 
further demonstrate that ZNF224 is a transcriptional repressor of AXL 
tyrosine kinase in CML, which plays a crucial role in Imatinib resistance in 
CML. 
Taken together, our results identify new mechanisms by which ZNF224 
transcription factor exerts an anti-oncogenic effect in CML and highlight the 
crucial role of ZNF224 in Imatinib responsiveness, thus providing 
convincing evidence that ZNF224 induction could play a role in overcoming 
Imatinib resistance in CML cells. 
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SOMMARIO 
Il fattore trascrizionale ZNF224, è stato recentemente descritto come un 
fattore proapoptotico in leucemia mieloide cronica (LMC), importante nel 
mediare l’apoptosi indotta dal farmaco ara-C. Più recentemente, abbiamo 
dimostrato che la proteina di fusione Bcr-Abl, regola negativamente 
l’espressione di ZNF224 in LMC, mentre l’inibizione di Bcr-Abl 
dall’inibitore tirosin-chinasico (TKI) Imatinib, usato come farmaco di prima 
linea in LMC, aumenta l’espressione di ZNF224. 
D’altra parte, Bcr-Abl, attraverso l’attivazione di Jak2, aumenta 
l’espressione del gene c-Myc, che è necessario per la trasformazione 
oncogenica indotta da Bcr-Abl in LMC. Coerentemente, l’inibizione di Bcr-
Abl da Imatinib porta ad una riduzione di c-Myc. Tale riduzione è 
fondamentale per la risposta ad Imatinib ed ai TKIs di nuova generazione. 
In questo lavoro, abbiamo dimostrato che ZNF224 è un nuovo repressore 
trascrizionale dell’oncogene c-Myc in LMC e coerentemente, riduce la 
proliferazione e la sintesi del DNA in LMC. 
In modo interessante, i nostri dati rivelano un ruolo cruciale per l’induzione 
di ZNF224 nel mediare la repressione dell’Imatinib su c-Myc in LMC. In 
aggiunta, dimostriamo che alterazioni nel sito di legame di ZNF224 sul 
promotore di c-Myc, significativamente riducono la repressione 
trascrizionale dell’Imatinib su c-Myc in cellule LMC, suggerendo un 
importante ruolo per questa regione per la risposta ad Imatinib. 
Successivamente, abbiamo inoltre riportato che l’AG490, un potente 
inibitore di Jak2, reprime c-Myc, almeno in parte, attraverso l’induzione di 
ZNF224. 
Un problema cruciale del trattamento con TKIs in LMC è legato alla 
possibilità di sviluppare resistenza a questi. Qui dimostriamo che 
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l’espressione di ZNF224 è più bassa in linee cellulari di LMC resistenti ad 
Imatinib e che la sua induzione dall’Imatinib è bloccata, ma può essere 
revertita dall’AG490. Consistentemente, il trattamento con AG490 o 
l’induzione di ZNF224 nelle cellule di LMC resistenti ad Imatinib, riduce 
l’espressione di c-Myc ed induce apoptosi. 
In aggiunta, dimostrate le implicazioni di ZNF224 nella risposta ad Imatinib, 
abbiamo ulteriormente dimostrato che ZNF224 è un repressore trascrizionale 
del recettore tirosin-chinasico AXL in LMC, che ha un ruolo fondamentale 
nella resistenza ad Imatinib in LMC. 
In conclusione, i nostri dati descrivono nuovi meccanismi anti-tumorali del 
fattore trascrizionale ZNF224 in LMC e suggeriscono un suo ruolo cruciale 
nella resistenza ad Imatinib, aprendo dunque la strada allo sviluppo di nuovi 
approcci molecolari per indurre l’espressione di ZNF224 nelle cellule di 
LMC. 
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1. BACKGROUND 
 
 
1.1 Chronic Myelogenous Leukemia 
 
Chronic Myelogenous Leukemia is a hematopoietic stem cell disorder 
characterized by an uncontrolled expansion of clonal bone marrow myeloid 
precursor cells, which are deregulated in their normal differentiation towards 
mature granulocytes (neutrophils, eosinophils and basophils). Finally, the 
deregulated differentiation and growth of myeloid precursor cells in the bone 
marrow is followed by the accumulation of these cells in the blood. 
CML is classified into three phases on the basis of clinical characteristics. 
CML begins in the chronic phase and can progress to an accelerated phase 
and finally to a blast crisis phase. In fact, blast crisis behaves like acute 
leukemia and represents the terminal phase of CML. The main causes of the 
progression from chronic phase to accelerated and blast crisis phases are 
mainly represented by the accumulation of new chromosomal 
abnormalities.[1]  
A crucial role in chronic myelogenous leukemia (CML) pathogenesis and 
progression is represented by the reciprocal chromosomal translocation 
between the long arms of chromosome 9 and chromosome 22 
t(9;22)(q34;q11) which causes the formation of Bcr-Abl fusion oncoprotein. 
Bcr-Abl fusion oncoprotein is characterized by a constitutive tyrosine kinase 
activity which activates proliferative and survival pathways and transcription 
factors, such as c-Myc, driving and sustaining the oncogenic transformation. 
[2,3,4,5,6] 
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Although the bone marrow transplantation represents the only curative 
treatment for CML, chemotherapy approaches using alkylating agents, 
interferon alfa 2b, steroids and antimetabolites such as cytarabine (ara-C), 
have been widely exploited and used for leukemia treatment, even though 
their mechanisms of action remain still largely unexplored and not extremely 
specific towards tumoral cells. 
Nevertheless, the wide exploration of the molecular mechanisms involved in 
CML pathogenesis and progression improved the therapeutic approaches 
and led to new first line treatments for CML, using Tyrosine-Kinase 
inhibitors (TKIs) targeting specifically the Bcr-Abl fusion oncoprotein. [7] 
Imatinib (Gleevec) was the first signal transduction inhibitor approved by 
FDA in 2001 for the treatment of CML and gives patients a normal life 
expectancy. Indeed Imatinib, by specifically targeting and blocking Bcr-Abl 
tyrosine kinase activity, inhibits the CML progression in the 65–75% of 
patients, allowing the re-growth of the normal proportions of maturing white 
blood cells. However, a proportion of leukemic cells persist in almost all 
patients and the treatment must be continued indefinitely. [8] 
Among the tyrosine kinase inhibitors targeting Bcr-Abl, other new 
generation TKIs, such as Nilotinib and the dual Bcr-Abl and Src kinase 
inhibitors such as Dasatinib and PD166326, have been developed and are 
now used for CML treatment. 
However, a crucial problem linked to TKIs treatment is that, possibly in all 
the CML phases, the residual leukemic cells of many CML patients 
accumulate new mutations in Bcr-Abl fusion protein or in other downstream 
signaling or effector molecules, thus resulting in a refractory response and 
resistance to TKIs. [9] In this context, several molecular studies contributed 
to reveal new molecular effectors strictly linked to TKIs resistance in CML, 
including LYN, FYN, and AXL. [10,11,12] Moreover, several findings showed 
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that increased expression of the c-Myc transcription factor, found in CML 
blast crisis, is strictly correlated with poor response to Imatinib. [13] 
Therefore, the identification of new molecular mechanisms implicated in 
CML pathogenesis, could lead to new diagnostic approaches and could be 
exploited as the basis for the development of new therapeutic approach in 
Imatinib-resistant CML. 
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1.2 c-Myc role in CML 
 
Bcr-Abl possesses a constitutive tyrosine kinase activity which drives the 
activation of a multitude of signaling pathways, including Jak2 [14], PI3K/Akt 
[15,16], Ras [17] and NF-kB [18], which can lead to the induction of several proto-
oncogenic transcription factors, playing a pivotal role in sustaining the 
oncogenic transformation in CML. 
c-Myc represents one of the crucial oncogenic transcription factors induced 
by Bcr-Abl pathways in CML. In fact, c-Myc plays a central role in the 
regulation of apoptosis, proliferation, differentiation, and tumorigenesis of 
hematopoietic cells and consistently, it is necessary for Bcr-Abl oncogenic 
transformation in CML.[19] More in details, Bcr-Abl induction of the c-Myc 
oncogene occurs mainly via Jak2 activation, which positively regulates c-
Myc protein stability and transcription, although the transcriptional factors 
involved in this regulation remain still largely unexplored. [20,21,22]  
Consistently, the inhibition of Bcr-Abl tyrosine kinase activity by Imatinib 
or new generation TKIs, strongly reduces c-Myc expression and 
hematopoietic tumoral features of CML cells. Moreover, the reduction of c-
Myc is a key step for Imatinib induced differentiation and apoptosis in CML; 
in accord, during CML blast crisis phase, elevated c-Myc levels are found 
and correlate with a refractory response to Imatinib [13,23,24]. 
A central role for c-Myc oncogene in CML oncogenic transformation is 
mainly linked to its function in increasing CML cell proliferation rate. 
Among others, c-Myc proliferative network in CML is strictly correlated to 
cyclin D1 and p21 regulation. In fact, c-Myc exerts a positive regulation on 
cyclin D1 expression, [27] while it decreases p21 expression in CML cells 
[28,29,30,31,32,33]. 
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Cyclin D1 and p21 genes are cell cycle regulators in CML. More in details, 
Cyclin D1 promotes the progression to G1/S phase of the cell cycle [34], while 
p21 blocks cyclin/CDK complexes and the proliferating cell nuclear antigen 
(PCNA), which is strictly correlated to S-phase, thus causing G1 and G2 cell 
cycle arrest [35,36,37]. 
Consistently, multiple options have been and are still considered to 
counteract CML progression targeting c-Myc. These options range from the 
direct inhibition of c-Myc protein or its regulators, to more genetic targeting 
approaches based on c-Myc promoter repression. 
In accord with the pivotal role of the Jak2 pathway in Bcr-Abl positive 
regulation of c-Myc oncogene in CML, different Jak2 kinase inhibitors 
which have been developed, such as AG490, rely most of their anti-
oncogenic effect on c-Myc downmodulation[20,22,38]. For these reasons, Jak2 
inhibitor molecules could provide a means to overcome Imatinib resistance 
in CML. However, further studies are needed to consider the pre-
clinical/clinical suitability of AG490 compound, eventually combined with 
first-line treatments [39].  
An AG490-related compound, WP-1066, has been already developed. WP-
1066 possesses biological activity at significantly lower concentrations 
compared to AG490 and blocks the Jak pathway in Acute Myeloid Leukemia 
(AML) cell lines, suppressing proliferation and inducing cell cycle arrest and 
apoptosis.  
In several c-Myc-driven tumors, including CML, c-Myc overexpression is 
due to its increased transcription; hence, blocking or hampering c-Myc 
promoter activation could represent a pertinent option to contrast c-Myc 
oncogenic transformation.  
c-Myc promoter is composed of two tandem principal promoters, termed P1 
and P2. The downstream promoter P2 represents the highest regulated c-Myc 
promoter region[41]. Upstream P1 and P2 promoters there is a nuclease 
12	
	
hypersensitive element (NHE) III1, a G-rich sequence, which has a 
regulatory role on c-Myc transcription and which is rich in binding sites for 
zinc-finger protein, such as ZF87 and MAZ. This region can modulate the 
activation or repression of c-Myc transcription. Indeed, the double helix form 
of this region allows the binding of RNA polymerases and other transcription 
factors; by contrast, the G-quadruplex form prevents the transcription factors 
interactions with the promoter and leads to the down-regulation of c-Myc 
transcription. 
Since G-quadruplexes play a crucial role in the repression of c-Myc 
oncogene, small-molecules that can specifically induce or stabilize the G-
quadruplex formation has been developed as promising anti-cancer drugs. 
[42,43]. However, only CX-3543 (Quarfloxin) small-molecule compound, 
which selectively stabilizes the c-Myc G-quadruplexes, has entered in phase 
II clinical trials for neuro-endocrine carcinomas so far. 
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1.3 AXL emerging role in response to Imatinib in CML 
 
As mentioned before, a critical problem linked to TKIs treatment in CML is 
the possibility to develop resistance to the treatment. 
In this context, many studies have been focused on the exploration of the 
molecular mechanisms correlated to TKIs resistance in CML in order to 
specifically target resistant cells and, hopefully, induce re-sensitization.  
As already mentioned, LYN, FYN and AXL molecules have been recently 
reported as strictly linked to drug resistance in cancer [10]. Interestingly, it has 
been demonstrated that AXL overexpression is a feature of several TKI-
resistant CML cell lines. Consistently, AXL knockdown re-sensitized TKI-
resistant CML cells to Imatinib and, by contrast, overexpression of AXL 
confers Imatinib resistance to Imatinib-sensitive CML cells. [12] 
Furthermore, a very recent study has reported that AXL is overexpressed in 
primary cells of CML patients compared to healthy individuals and its 
expression is further increased in patients with resistance to Bcr-Abl TKIs, 
compared to the sensitive counterpart. 
Most interestingly, AXL blocking with the new small inhibitor BGB324 
showed intriguing additive therapeutic effects in combination with Imatinib 
in CML cell lines and, importantly, decreases the growth and induces 
apoptosis of Bcr-Abl TKI-resistant cells, mutated in Bcr-Abl [44]. Altogether, 
the entry in clinical trials of the first AXL-branded inhibitor in 2013, 
followed by the developing of this new promising AXL inhibitor BGB324, 
enforce the role of AXL as an anticancer target, especially in CML. 
AXL is a Receptor Tyrosine Kinase (RTK), belonging to the TAM family 
(TYRO3, AXL, and MER), discovered in 1991 and reported as an 
unidentified transforming gene in CML. [45] 
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TAM proteins comprise a β-stranded N-terminal lobe at the extracellular 
region, composed of two immunoglobulin like (Ig-like) domains and two 
fibronectin type III repeats (FTIII). A transmembrane region connects the 
extracellular region to a helical C-terminal lobe, containing an intracellular 
kinase domain. Once AXL has been activated, the intracellular region is 
phosphorylated and trans-activates, by cross-phosphorylation, downstream 
signaling effectors. [46] 
A variety of mechanisms can activate AXL, but the most common is the 
ligand-dependent activation exerted by GAS6, which leads to the formation 
of a dimer consisting of two AXL molecules, bound to two GAS6 molecules. 
[47] 
The phopsphorylated AXL protein activates different signaling pathways, 
mainly involved in cell survival. More in details, AXL activates RAS and 
PI3K/Akt pathways, thus resulting in an activation of multiple cell survival 
proteins such as: IKK, MDM2 and mTOR. By contrast, there is an 
inactivation of pro-apoptotic proteins, such as the Bcl-2 family member 
BAD. [48] 
Intriguingly, AXL also crosstalks with other RTKs, such as VEGFR [49], 
EGFR [50], and MET [51], influencing their signaling as well. This further 
enforces the complex regulatory role of AXL in different mechanisms of 
drug resistance and even metastasis. 
Apart from ligand-dependent activation of AXL, ligand-independent 
activation can also occur, when AXL is greatly overexpressed; this is 
consistent with the strict correlation between AXL overexpression and its 
enhanced function in tumor cells. [47] 
Regarding AXL regulation, it has been described that AXL gene expression 
is modulated by CpG methylation of its promoter and its transcription is 
mediated by the transcription factors SP1 and SP3 [52]. Moreover, it has been 
reported a post-transcriptional down-regulation of AXL mRNA by two 
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specific microRNAs, miR-34a and miR 199a/b, which are suppressed by 
promoter methylation in several solid tumors [53]. 
Nevertheless, although AXL overexpression has been found in different 
cancer types and correlates with poor prognosis, AXL regulation needs to be 
still largely investigated. 
These studies could pave the way to develop new molecular tools to 
counteract tumor progression and, most importantly, TKIs resistance in 
CML. 
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1.4 Role of ZNF224 transcription factor in CML 
 
ZNF224 is a Kruppel-like zinc-finger protein, which consists of 707 
aminoacids. It comprises a C-terminal region, containing 19 tandemly 
repeated C2H2 zinc finger domains and an N-terminal region, containing the 
KRAB-A repressor domain of 45 aminoacids [54]. 
Through its KRAB repressor domain, ZNF224 recruits the KAP-1 co-
repressor complex and the arginine methyltransferase type II, PRMT5, to 
repress gene transcription [55,56,57]. 
Initially identified as the transcriptional repressor of Aldolase A, ZNF224 
has been further reported as a transcriptional repressor of the mitochondrial 
carrier citrate gene as well, thus highlighting its role in controlling cell 
metabolism [58]. 
Complex new roles have been recently described for ZNF224 in regulating 
positively or negatively cancer progression, acting respectively as an 
oncogene or oncosuppressor, depending on different tumoral contexts and 
the interaction with specific sets of interactors [59]. 
The first oncogenic role for ZNF224 was reported in bladder carcinogenesis, 
in which ZNF224 exerts its tumoral effect by interacting with DEPDC1 
protein [60]. Moreover, it has been recently showed that ZNF224 acts as an 
oncogene in breast cancer cells, increasing the transcription of miR-663, 
which plays crucial roles in the initiation and progression of the malignancy 
[61]. 
Importantly, we have recently highlighted a role for ZNF224 as an oncogene 
in hematological malignancies. Indeed, we demonstrated a significative 
correlation between ZNF224 and cyclin D3 expression in Chronic 
Lymphocytic Leukemia (CLL) patients, further reporting that ZNF224 
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transcriptionally activates cyclin D3 expression in CLL, thus resulting in an 
increased CLL cell growth. Consistently, we further demonstrated the 
involvement of ZNF224 in fludarabine-resistance mechanisms of CLL, 
showing that fludarabine-induced apoptosis is inhibited by ZNF224 [62].  
The oncosuppressor function for ZNF224 instead, has been clearly 
established in CML. In this context, it has been found that ZNF224 
modulates the transcription in a DNA-binding-independent mode, by acting 
as a transcriptional cofactor of the Wilms Tumor protein 1 (WT1), a pro-
survival transcription factor highly expressed in CML. Interestingly, 
ZNF224 affects the balance between the antiapoptotic and proapoptotic WT1 
target genes in favor of the latter in CML. More in details, ZNF224, acts as 
a co-activator of WT1 on VDR, Bax and Bak pro-apoptotic genes, while it 
counteracts WT1 positive regulation of the anti-apoptotic A1/Bfl1 and Bag3 
genes. Moreover, we have recently identified a new mechanism by which 
ZNF224 acts in the fine tuning of WT1-dependent gene expression, leading 
to a positive regulation on the Interferon regulatory factor-8 (IRF8) gene 
expression in CML cells. IRF8 is a tumor suppressor in some leukemias and 
its expression is repressed by WT1 [63]. We demonstrated that WT1 
repressive activity on IRF8 promoter is counteracted by ZNF224 and that 
ZNF224 induction by cytarabine (ara-C) is able to restore IRF8 expression 
in CML cells [64]. Consistently, we also demonstrated that ZNF224 induction 
is necessary for ara-C-induced apoptosis [65]. 
CML is a myeloproliferative disorder in which the oncogenic progression is 
driven by Bcr-Abl fusion protein, which promotes uncontrolled proliferation 
and anti-apoptotic processes [66,67]. However, these processes remain to be 
largely characterized at a molecular level. 
Starting from these findings, revealing the significant role of ZNF224 in ara-
C mediated apoptosis in CML, we further clarified whether ZNF224 was a 
Bcr-Abl downstream target. 
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As first, we reported a ZNF224 down-modulation in both Bcr-Abl positive 
cell lines and in primary CML samples, compared to Bcr-Abl negative 
counterparts and, subsequently, we found that the inhibition of Bcr-Abl 
tyrosine-kinase activity by Imatinib or new generation TKIs triggers 
ZNF224 transcriptional up-regulation. Moreover, we reported a good 
correlation between ZNF224 expression at diagnosis and Imatinib 
responsiveness in CML patients, further suggesting a potential role for 
ZNF224 in Imatinib responsiveness. Furthermore, exploring Bcr-Abl 
negative regulation of ZNF224 expression in CML, we indentified WT1 as 
a direct transcriptional repressor of ZNF224, downstream Bcr-
Abl/phosphatidylinositol-3 kinase (PI3K)-Akt pathway [68].  
Since we previously observed that ara-C reduces WT1 expression in CML 
cells [65], the identification of WT1 as a transcriptional repressor of ZNF224 
gene in CML well correlates with ZNF224 induction by ara-C treatment. 
Altogether, our findings are consistent with the hypothesis that different 
signaling pathways induced by ara-C and Imatinib could converge on 
ZNF224 induction, via downmodulation of WT1. 
In addition, these molecular results also suggest the existence of a fine-
regulatory loop in CML, by which WT1 transcriptional repression on 
ZNF224 could prevent ZNF224/WT1 complex formation and function, 
further enhancing CML cells survival. On the contrary, the induction of 
ZNF224 expression allows the formation of ZNF224/WT1 complex, which 
positively modulates the expression of proapoptotic genes. 
In the present study, starting from a good anti-correlation between ZNF224 
and c-Myc expression observed in CML cells treated with Imatinib, we 
demonstrate that ZNF224 is a novel transcriptional repressor of c-Myc and 
is responsible for Imatinib-mediated downregulation of c-Myc in CML.  
 
19	
	
Moreover, exploring ZNF224 role in Imatinib resistance we further showed 
that ZNF224 is also involved in negative regulation of AXL that, as 
mentioned before, represents a molecular effector strictly correlated to TKIs 
resistance in CML.  
Altogether, our data revealed appealing basis to consider ZNF224 induction 
for the development of new therapeutic approach in CML, hopefully, 
overcoming drug resistance. 
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2. AIM OF THE WORK 
 
Recently, we demonstrated a crucial pro-apoptotic role for 
ZNF224 transcription factor in CML. In fact, ZNF224 acts as a 
transcriptional cofactor of WT1 and positively regulates the 
expression of different WT1 pro-apoptotic target genes, such as 
VDR, bax, bak and IRF8, while it suppresses A1/Bfl1 and bag3 
anti-apoptotic genes in CML. 
Most interestingly, we recently found that ZNF224 is negatively 
regulated by Bcr-Abl fusion oncoprotein and, consistently, it is 
positively regulated by Imatinib and next-generation TKIs in CML 
cells. 
These data provided the basis for the present study, aimed to better 
characterize the regulatory role of ZNF224 in CML. 
Prompted by a good anti-correlation between ZNF224 and c-Myc 
expression in CML cells, the first aim of the present study was to 
investigate ZNF224 as a potential novel transcriptional repressor 
of c-Myc oncogene, downstream Bcr-Abl in CML.  
In addition, our recent findings showing that ZNF224 is 
significantly down-regulated in CML patients with poor response 
or resistance to Imatinib led us to further investigate the molecular 
mechanisms underlying ZNF224 involvement in Imatinib 
responsiveness in CML. 
The identification of novel targets of ZNF224 and a better 
characterization of the pathways downstream Bcr-Abl involved in 
the down-regulation of ZNF224 expression could pave the way to 
develop new prognostic and therapeutic approaches in CML based 
on ZNF224 induction, hopefully useful to overcome drug 
resistance. 
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3. MATERIALS AND METHODS 
 
	
Cell lines and Reagents 
HEK293T human cell line was cultured in Dulbecco’s modified Eagle’s 
medium (Sigma-Aldrich) supplemented with 10% fetal calf serum, 100 
µg/ml streptomycin-penicillin mix (Sigma-Aldrich) at 37°C in 5% CO2.  
K562 and Jurl-MK1 human cell lines were cultured in RPMI 1640 (Sigma-
Aldrich) supplemented with 10% fetal calf serum and 100 µg/ml penicillin-
streptomycin mix (Sigma-Aldrich) at 37°C in 5% CO2. 
K562 cells were treated with 1 µM Imatinib (Novartis Pharma), 100 µM or 
50 µM AG490 (Sigma-Aldrich), 500ng/ml Puromycin (Sigma-Aldrich). 
K562 Imatinib were estabilished as described in [10], in wich it is described 
that the TKIs resistance is indipendent by mutations in Bcr-Abl. 
K562 Nilotinib resistant clones were estabilished as described in [69] Jurl-
MK1 Imatinib resistant clones were estabilished as described in [80]. 
 
 
 
RNA isolation, reverse transcription and real-time qPCR 
Total RNA was isolated using the Quick-RNA™ MiniPrep Plus (Zymo 
research) according to the manufacturer’s protocol. 1 µg of RNA was reverse 
transcribed using the iScript Reverse Transcription Supermix for RT-qPCR 
(Bio-Rad), as recommended by the manufacturer. Real-time PCR was 
carried out in a Real-Time CFX 69 System (Bio-Rad, Berkeley, CA, USA) 
using the Master Mix SYBR Green (Bio-Rad). 
 
 
The sequences of the primers are reported in the table below: 
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ZNF224 F 5′-GGGCTGTCTTGGCACAATTC-3′ 
R 5′-TTGCCTCCTTGAACGTGGTC-3′ 
c-Myc F 5’-ACTCTGAGGAGGAACAAGAA-3’ 
R 5’- TGGAGACGTGGCACCTCTT-3’ 
AXL F 5’-GGTGGCTGTGAAGACGATGA-3’ 
R 5’- CTCAGATACTCCATGCCACT-3’ 
Abl F 5’-GATGTAGTTGCTTGGGACCCA-3’ 
R 5’- TGGAGATAACACTCTAAGCATACT-3’ 
β2 microglobulin F 5’- CCGTGGCCTTAGCTGTGCT-3’ 
R 5’- TCGGATGGATGAAACCCAGA-3’ 
 
The relative quantification in gene expression was determined using the 
ΔΔCT method. 
 
Cell lysates and western blot assays 
Total cell lysates were prepared by homogenization in modified RIPA buffer 
as previously described [81]. The membranes were incubated with the 
following antibodies: anti-ZNF224 (rabbit polyclonal, T3) diluted 1:300 in 
Super-Block Blocking Buffer (Thermo Scientific, Waltham, MA, USA), 
anti-c-Myc, anti-Cyclin D1, anti-p21 and anti-PCNA (Santa Cruz 
Biotechnology, CA, USA) diluted 1:500, anti-G3PDH (Santa Cruz 
Biotechnology, CA, USA) diluted 1:1000, anti-phospho-Jak2 (Santa Cruz 
Biotechnology, CA, USA) diluted 1:200, anti-β-actin (Sigma) diluted 
1:1000, anti-Flag and anti-ß-Tubulin (Upstate, Lake Placid, NY) diluted 
1:1000, anti-AXL (Santa Cruz Biotechnology, CA, USA) diluted 1:300. 
Signals were detected with ImmunoCruz Western Blotting Luminol Reagent 
(Santa Cruz Biotechnology). 
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Transient and stable transfection 
HEK293 cells were transiently transfected using Metafectene (Biontex) with 
either 0.5 µg or 1 µg or 2 µg of ZNF224-Flag expression plasmid. As control, 
1.5 µg of 3X-Flag empty vector were transfected.  
K562 cell lines were transiently transfected using Lipofectamine 2000 
(Thermo Fisher) with either 1.5 µg of ZNF224-Flag expression plasmid or 
two different shRNA specific for ZNF224 (shC3 and shE7). As control, 1.5 
µg of 3X-Flag empty vector or shRNA specific for GFP were transfected.  
To obtain stable ZNF224 knock-down, K562 transfected cells, were cultured  
in RPMI supplemented with 10% FBS and 500 ng/mL Puromycin (Sigma-
Aldrich).  To obtain stable ZNF224 over-expressing clones, K562 
transfected cells with ZNF224-Flag(Neo) or 3X-Flag(Neo) expression 
plasmid, were cultured  in RPMI supplemented with 10% FBS and 500 
µg/mL Neomycin (Sigma-Aldrich). 
 
Luciferase reporter assays 
HEK293 cells were transiently transfected using Metafectene (Biontex) with 
either a luciferase reporter plasmids containing the c-Myc promoter (0.2 µg 
of c-Myc Del-2/Del-3/Del-6 plasmid) or AXL promoter (0.5 µg of AXL p6 
plasmid) and pRL-CMV plasmid coding for the renilla luciferase to 
normalize (1:10 the ratio between renilla and c-Myc constructs; 1:20 the ratio 
between renilla and AXL construct). c-Myc Del-2 and Del-3 plasmids were 
a gift from Bert Vogelstein (Addgene plasmid # 16603) [82]. c-Myc Del-6 
plasmid was a gift from Joan Massague (Addgene plasmid # 14969) [83]. 
AXL p6 plasmid was a gift from Heike Allgayer [52]. HEK293 cells were 
co-transfected with 0.2 or 0.4 or 0.6 µg or 0.8 µg of ZNF224-Flag expression 
plasmid, or with the 3X-Flag empty vector, as negative control. 
K562 cell lines were transiently transfected using Lipofectamine 2000 
(Thermo Fisher) with either a luciferase reporter plasmids containing the c-
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Myc promoter (0.2 µg of c-Myc Del-2/Del-3/Del-6 plasmid) or AXL 
promoter (0.5 µg of AXL p6 plasmid) and pRL-CMV plasmid coding for the 
renilla luciferase to normalize (1:10 the ratio between renilla and c-Myc 
constructs; 1:5 the ratio between renilla and AXL construct). K562 cells were 
co-transfected with 1 µg of ZNF224-Flag expression plasmid, or with the 
3X-Flag empty vector, as negative control. 
After 48h, luciferase activity was measured in HEK293 or K562 cells, using 
the Dual-Luciferase Reporter Assay System (Promega Corporation, WI, 
USA), according to the manufacturer’s instructions. 
 
Chromatin Immunoprecipitation Assay 
Cross-linked chromatin was prepared from HEK293 or K562. Briefly, 6 
milions cells were cross-linked with 1.4% of fixing solution (11% HCHO, 
100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 50 mM Hepes, pH 8.0). Next, 
cells were harvested in 1 ml of cell lysis buffer (5 mM PIPES, pH 8.0, 85 
mM KCl, 0.5% Nonidet P-40, protease inhibitors). Collected nuclei were 
resuspended in 300 µl of nuclear lysis buffer (50 mM Tris-HCl, pH 8.0, 10 
mM EDTA, 0.8% SDS, and protease inhibitors). DNA was sheared by 
sonication. Sonicated DNA (500-1000bp) was diluted in dilution buffer (1:3) 
(10 mM Tris-HCl, pH 8.0, 0.5 mM EGTA, 1% Triton X-100, 140 mM NaCl, 
protease inhibitors) and pre-cleared with protein A/G plus-agarose (Santa 
Cruz Biotechnology, Santa Cruz, CA) at 4 °C for 1 h. The precleared nuclear 
extract was divided in two: one was used for negative immune-precipitation 
control, incubated with Anti – IgG (Sigma-Aldrich) antibody and the other 
was incubated with Anti-ZNF224 antibody (G16 – Santa Cruz 
Biotechnology, Santa Cruz, CA). After antibody incubation, A/G plus-
agarose beads (Santa Cruz Biotechnology, Santa Cruz, CA) were added to 
the samples and incubated for 1 h at 4°C , then collected by centrifugation 
and  washed four times with LSB buffer (10mM Hepes pH 7.8, 250mM 
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NaCl, 5mM EDTA, 0.1% NP40, 1 mM sodium orthovanadate, 50mM NaF) 
and once with TE buffer (1 mM Na-EDTA, 10 mM Tris-HCl, pH 8.0). After 
washing, the beads were resuspended in 100 µl of TE buffer, and incubated 
at 65 °C overnight to reverse the cross-link. The day after, 0.5% SDS and 0.5 
mg/ml proteinase K were adjusted in the samples. After, the samples were 
incubated for 3 h at 50 °C. Finally, by phenol-chloroform extraction, DNA 
was purified. ChIP samples were then analyzed by RT-qPCR using specific 
primers for: c-Myc promoter (P2 region) (Fw: 5’-
TCGGGGCTTTATCTAACTCG-3’, Rev: 5’-
GCTGCTATGGGCAAAGTTTC-3’) and Unrelated c-Myc region (5’-
GAAGCGGAAATTGCAGTGAG-3’, Rev:5’-
AGGGATAGGGTCTTGCTACG-3’). 
The ΔΔCt related to the total input chromatin (% of input) of 
immunoprecipitated ZNF224 P2 Myc region and c-Myc unrelated region 
relative were compared.  
 
Cell counting and Annexin V assay 
For cell number determination of K562 cells stably silenced for ZNF224, 
cells were plated at 1 x 104/mL density in a 24 well plate and viable cells 
were counted from 1 to 4 days by trypan blue exclusion every 24 hours.  For 
cell doubling time determination, 4 x 104/mL cells were plated in a 12 well 
plate  and viable cells were counted every 24 hours from plating and re-plated 
at initial density. Cell doubling time was calculated by Log2 (n° counted 
cells/n° plated cells). 
For annexin V staining, 1 x 105 cells were washed twice in cold PBS, then 
resuspended in cold annexin V-binding buffer (5 M NaCl, 1 M CaCl2, 1M 
HEPES buffer/NaOH pH 7.4) and stained with Annexin V-APC (550474, 
BD Pharmingen). After incubation in the dark on a shaker for 15 min at 4°C, 
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cells were analyzed on FACS flow cytometer (BD Biosciences Accuri C6 
Flow Cytometer). 
Site-directed mutagenesis of c-Myc promoter reporter construct 
Mutant constructs were generated using the QuikChange® site-directed 
mutagenesis kit (Stratagene) using c-Myc del-6 (−109 to +334) as the DNA 
template. Mutagenesis was performed in according to the manufacturer’s 
instructions. Complimentary oligonucleotide for mutation of the ZNF224 
binding sites to convert GCAGAGCTG to GCGCGGCTG, on c-Myc 
promoter, was synthesized (5’ - 
GTGGAAGAGCCGGGCGAGCGCGGCTGCGCTGCGGGCGTCC -3’ N 
bp=40; %GC=80; %MM=7.5; Tm=89.925°C). Successful incorporation of 
the mutations was confirmed by DNA sequencing. 
 
BrdU incorporation assay 
Cell proliferation measured with 5-bromo-20-deoxy-uridine labelling was 
performed with a detection kit (Detection Kit II, Roche Diagnostics 
Corporation, Indianapolis, IN, USA) following the manufacturer’s 
instructions. Briefly, K562 cells stable silenced for ZNF224 were plated 3x 
105 per 1.5mL into 6-well plates. While, 4x105 K562 cells were transiently 
transfected for 24 hours with 7µg of 3X-Flag or ZNF224-Flag expression 
vectors, and then 2x105 of these cells per 1.5mL were plated into 6-well 
plates. Then, 10 mM BrdU was added to the cultures, and, after 3 hours or 5 
hours, respectively stable silenced cells or transiently transfected cells were 
collected, fixed with ethanol, and incubated with anti-BrdU monoclonal 
antibody. The percentage of BrdU incorporation was measured on FACS 
flow cytometer (BD Biosciences Accuri C6 Flow Cytometer). 
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Caspase Activity Measurement 
After treatment, K562 cells were lysed for 30 min at 4°C in lysis buffer [84], 
and lysates were cleared at 10,000 g for 15 min at 4°C. Each assay was done 
with 25 µg of protein. Cellular extracts were incubated in a 96-well plate 
with Ac-DEVD-AMC (7-amino-4-methylcoumarin) or Ac-LEHD-AMC 
(0.2 mmol/L) for various times at 37°C as described earlier. [84] 
 
Samples from CML patients and healthy donors  
Human Peripheral blood mononuclear cells (PBMC) were obtained from 3 
healthy donors and 6 CML patients with informed consent, according to the 
Declaration of Helsinki and recommendations of an independent scientific 
review board. 
 
Statistical analysis  
All data are presented as mean±SD. The Student’s t test was used to evaluate 
the statistical signicance of differences using the non-parametric Mann-
Whitney test, with a p value < 0.05 or < 0.005 indicating a signicant 
difference. 
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4. RESULTS 
 
4.1 ZNF224 exerts a transcriptional repression on c-Myc expression  
We previously showed that Bcr-Abl fusion protein negatively regulates the 
expression of the proapoptotic transcription factor ZNF224 in CML. 
Consistently, Bcr-Abl inhibition by Imatinib and new generation tyrosine 
kinase inhibitors (TKIs), such as Dasatinib and Nilotinib, increased ZNF224 
expression and was accompanied by apoptosis induction in CML cells. [68] 
The c-Myc oncogene is a target of Bcr-Abl transforming activity, indeed 
Bcr-Abl inhibition by Imatinib strongly reduces c-Myc expression. 
Coherently, we observed that ZNF224 induction by Imatinib well correlated 
with c-Myc oncogene reduction and cell death induction in K562 CML cells 
(fig.1A). 
Moreover, in silico analysis revealed three putative ZNF224 binding sites on 
a c-Myc promoter region extending from -1237 to +334, including the two 
transcription start sites (TSS) P1 and P2 (fig.1B, upper panel), thus 
suggesting that c-Myc gene could be a target of ZNF224 transcriptional 
repression in CML. 
To explore whether c-Myc promoter activity was repressed by ZNF224 and 
to identify the potentially involved regions, three luciferase reporter 
plasmids containing progressive deletions of the c-Myc promoter (Fig.1B 
lower panel) were introduced into HEK293 cells and luciferase activity was 
analyzed in the presence of increasing amounts of the ZNF224 expression 
vector. The result of this experiment showed that the transcriptional activity 
of c-Myc promoter was progressively decreased by the overexpression of 
ZNF224 in all three deletion mutants (Fig.1C), thus indicating that ZNF224 
repression on c-Myc gene occurs through ZNF224 binding at the high 
regulatory P2 region, included in the DEL-6 construct.  
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Coherently, ZNF224 overexpression in HEK293 cells was associated with a 
dose-dependent reduction of c-Myc protein levels and with a decrease in the 
protein levels of cyclin D1, a positive c-Myc target gene (Fig.1D).  
Chromatin immunoprecipitation assays (ChIP) in HEK293 cells were 
performed to validate ZNF224 binding on the P2 region of the c-Myc 
promoter. Chromatin was immune-precipitated with a ZNF224 antibody and 
analyzed by RT-qPCR, using oligonucleotides flanking the P2 region. As 
shown in figure 1E, the results confirmed ZNF224 occupancy on the P2 
region of c-Myc promoter (P2 region). 
Moreover, in agreement with the lower expression of ZNF224 in K562 CML 
cells compared to HEK293 cells, we found that the basal transcriptional 
activity of DEL-6 construct was higher in K562 CML cells compared to 
HEK293 (Fig. 1F). 
These data demonstrate that ZNF224 is able to bind c-Myc promoter to 
repress its transcription. 
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Figure 1: ZNF224 reduces c-Myc expression via a transcriptional mechanism. 
(A) K562 cells were treated with 1 µM Imatinib for 24h or vehicle only (DMSO) as control. 
ZNF224, c-Myc and cleaved caspase-3 protein levels were analyzed by Western blot. ß-actin was 
used as loading control. One representative blot out of two performed is shown. Cell death was 
evaluated by annexin V staining followed by flow cytometry. Results represent the means +/- SD 
of two independent experiments. (B) Schematic representation of c-Myc promoter region and 
position of the three putative ZNF224 binding sites (First region, P1 region and P2 region) (upper 
panel). Schematic representation of DEL-2, DEL-3 and DEL-6 deletion constructs of the c-Myc 
promoter  (lower panel). (C)  Luciferase reporter assay showing c-Myc promoter activity. 0.2 µg 
of c-Myc deletion constructs (DEL-2, DEL-3 and DEL-6) were transfected into HEK293 cells 
together with 0.2µg, 0.4µg, 0.6µg of 3X-Flag ZNF224 or 3X-Flag expression plasmid as control 
(-). 24h hours after transfection, promoter activity was determined by normalizing Firefly to 
Renilla luciferase activity. Error bars represent standard deviations of two independent 
experiments. ZNF224 overexpression was controlled by Western Blot analysis. Tubulin was used 
as loading control. One representative blot out of three performed is presented. (D) Western blot 
analysis of ZNF224-Flag, c-Myc and cyclin D1 protein levels in HEK293 cells transfected with 
0.5µg, 1µg and 2µg of 3X-Flag ZNF224. G3PDH was used as loading control (left panel). 
Densitometric analysis of c-Myc protein levels. Results were normalized by arbitrarily setting the 
densitometry of cells transfected with 0.5µg of 3X-Flag ZNF224 to 1. Error bars represent 
standard deviations of three independent experiments; *= p-value <0.05. (E) ChIP assay 
performed in HEK293 cells with an anti-ZNF224 antibody. Immunoprecipitation with non-
specific IgG was used as negative control. Quantitative real-time PCR analysis was performed 
using specific c-Myc primers, covering ZNF224 putative binding element on the c-Myc promoter 
(P2 region: -30/+150 to TSS P2). A region downstream c-Myc locus was used as negative control 
(c-Myc unrelated region). Shown is the amount of immunoprecipitated P2 region or c-Myc 
unrelated region relative to that present in total input chromatin (% of input). Error bars indicate 
the mean value +/- SD of two independent experiments. (F) DEL-6 transcriptional activity in 
HEK293 cells and K562 CML cells. 0.2µg of the DEL-6 construct were transfected into HEK293 
cells and K562 cell. 24h after transfection, promoter activity was determined by normalizing 
firefly to Renilla luciferase activity. DEL-6 activity was compared to CMV Luciferase activity 
obtained in each cell line. Error bars represent standard deviations of two independent 
experiments. ZNF224 protein expression was measured by Western Blot analysis. Tubulin was 
used as loading control. One representative blot out of two performed is shown. 
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4.2 ZNF224 binds to a regulatory element in the c-Myc promoter in 
CML 
Next, we further confirmed ZNF224 transcriptional repression on c-Myc in 
K562 CML cells and investigated the region of c-Myc promoter involved in 
this repression. To this aim, we performed a site-directed mutagenesis of 
three nucleotides within the ZNF224 binding consensus on the DEL-6 
construct, thus obtaining the mutant c-Myc promoter construct DEL-6 MUT 
(Fig. 2A). 
Next, we compared ZNF224 transcriptional repression on both wild-type and 
mutant c-Myc promoter in K562 cells. K562 cells were transfected with 
DEL-6 or DEL-6 MUT constructs together with the ZNF224-Flag 
expression vector and luciferase activity was measured. As expected, 
ZNF224 overexpression significantly reduced DEL-6 luciferase activity, 
while it was not able to repress the luciferase activity of DEL-6 MUT 
construct (Fig. 2B).  
Furthermore, by introducing DEL-6 wild-type or DEL-6 MUT constructs in 
K562 cells stably knocked-down for ZNF224 with two different shRNA 
(shC3 and shE7) we observed an increased DEL-6 wild-type promoter 
activity, while no significant variations in DEL-6 MUT luciferase activity 
were detected (Fig. 2C). 
Accordingly, a substantial reduction in c-Myc protein levels was found when 
ZNF224 was overexpressed in K562 CML cells (Fig.2D), while the stable 
knock-down of ZNF224 in shC3 and shE7 clones was associated with an 
increased c-Myc protein levels (Fig.2E). 
c-Myc oncogene plays a role in regulating cell death and survival but is also 
involved in CML oncogenic transformation, mainly increasing cell 
proliferation rate. 
Hence, to further support ZNF224 repression on c-Myc, we evaluated CML 
cell proliferation rate in K562 cells stably knocked-down for ZNF224 with 
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two different shRNA (shC3 and shE7). Coherently with c-Myc increased 
levels, ZNF224 knocked-down cells showed an increased cell number (Fig. 
3A) and doubling time (Fig. 3B). Moreover, BrdU incorporation assays 
demonstrated a significant increase in DNA synthesis of ZNF224 silenced 
K562 cells (Fig. 3C), while DNA synthesis was significantly decreased when 
ZNF224 was overexpressed in K562 cells (Fig. 3D). In addition, by western 
blot assay we consistently showed that c-Myc reduction after ZNF224 
overexpression was accompanied by a reduction in cyclin D1 and PCNA, 
while p21 was increased (Fig. 3E). 
Taken together, these data showed that ZNF224 exerts a transcriptional 
repression on c-Myc expression in CML cells and coherently inhibits cell 
proliferation. Furthermore, our results revealed that a binding element near 
to P2 transcriptional start site is necessary for ZNF224 repression on the c-
Myc gene in CML cells.  
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Figure 2: ZNF224 binding on P2 region is crucial for its repression activity on c-Myc 
promoter in CML. 
(A) Schematic representation of DEL-6 MUT and DEL-6 WT constructs. (B) Luciferase reporter 
assay showing ZNF224 effect on the promoter activity of DEL-6 WT and DEL-6 MUT constructs 
in K562 cells. K562 cells were transfected with DEL-6 WT or DEL-6 MUT together with 1µg of 
3X-Flag ZNF224 or 1µg 3X-Flag empty vector as control (-). 48 hours after transfection promoter 
activity was determined by normalizing Firefly to renilla luciferase activity. Shown is promoter 
activity compared to control cells (-). Error bars represent standard deviations of three 
independent experiments; **= p-value <0.005. (C) K562 cells stably silenced with two different 
shRNA versus ZNF224 (shC3 and shE7) or with a control shRNA (shGFP) were transfected with 
DEL-6 WT or DEL-6 MUT. 24h hours after transfection the Firefly luciferase activity was 
measured and normalized to Renilla luciferase activity. Error bars represent standard deviations 
of three independent experiments; **= p-value <0.005. (D) Western blot analysis of ZNF224-
Flag and c-Myc protein levels in K562 transfected with 1µg of 3X-Flag ZNF224 or 1µg 3X-Flag 
empty vector as control (-). G3PDH was used as loading control. (E) Western blot analysis of 
ZNF224 and c-Myc protein levels in K562 cells stably silenced for ZNF224 (shC3 and shE7) and 
control K562 cells (shGFP). G3PDH was used as loading control.  Arrow indicates the specific 
band 
 
 
 
36	
	
 
 
   3A                                                         3B 
 
3C                                                       3D                                   
 
 
                  3E 
                                                 
Figure 3: ZNF224 hampers CML cells proliferation  
(A) Proliferation rate of K562 cells stably silenced for ZNF224 (shC3 and shE7) and control K562 
cells (shGFP) evaluated by cell counting. Viable cells were counted by trypan blue exclusion 
every 24 hours for 4 days. Error bars represent standard deviations of three independent 
experiments.  
(B) Every 24 hours, viable cells were counted by trypan blue exclusion and cell doubling time 
was calculated. Error bars represent standard deviations of two independent experiments. (C) 
Relative BrdU incorporation in K562 cells stably silenced for ZNF224 (shE7) compared to control 
K562 cells (shGFP). Error bars represent standard deviations of two independent experiments. 
Percentage of BrdU incorporation of one representative plot out of two is presented. (D) Relative 
BrdU incorporation in K562 cells transiently transfected with 1.5µg of 3X-Flag ZNF224 
expression vector compared to K562 cells transfected with 3X-Flag empty vector, used as control 
(-). Error bars represent standard deviations of three independent experiments (*= p-value < 0.05). 
(E) Western blot analysis of ZNF224-Flag, c-Myc, cyclin D1, p21 and PCNA levels. Tubulin was 
used as loading control. One representative blot out of two performed is presented. Arrows 
indicate specific bands. 
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4.3 ZNF224 mediates the Imatinib-dependent transcriptional repression 
of c-Myc in CML and induces cell death in Imatinib-resistant CML cells  
 
Prompted by these data, we decided to investigate the involvement of 
ZNF224 in Imatinib-dependent transcriptional repression on c-Myc 
oncogene in CML, which represents a key step for Imatinib responsiveness 
[13,23,24]
.  
At first, by ChIP assays we verified ZNF224 binding on the c-Myc promoter 
in K562 CML cells and Imatinib effect on this binding. To this aim, K562 
cells were incubated in absence or presence of Imatinib 1µM for 24h, after 
which chromatin was immunoprecipitated with a ZNF224 antibody and 
analyzed by real-time qPCR with oligonucleotides covering the P2 region of 
the c-Myc promoter. The obtained results revealed a basal ZNF224 
occupancy on P2 region of the c-Myc promoter, that was significantly 
increased by Imatinib treatment (Fig. 4A). 
Further, we investigated the effect of Imatinib on the activity of the c-Myc 
promoter constructs DEL-6 WT and DEL-6 MUT. As shown in figure 4B, 
DEL-6 promoter activity was significantly reduced by Imatinib treatment, 
while a lower repression was found on DEL-6 MUT. In agreement with the 
observed ZNF224 induction by Imatinib (WB Fig.4A), these results indicate 
that ZNF224 binding on c-Myc promoter is required for Imatinib repression 
of the c-Myc gene.  
Subsequently, we found that the reduction of c-Myc mRNA and protein 
levels by Imatinib was significantly impaired by ZNF224 knock-down (Fig. 
4C and 4D) and, as expected, ZNF224 knock-down also impaired Imatinib 
induced cell death (Fig. 4E). 
Collectively, these results clearly show that the induction of ZNF224 
mediates Imatinib transcriptional repression on c-Myc, thus revealing an 
additional mechanism by which ZNF224 transcription factor contributes to 
Imatinib responsiveness in CML. 
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Prompted by these results, we explored the implication of ZNF224/c-Myc 
axis in Imatinib resistance. We investigated ZNF224 and c-Myc regulation 
by Imatinib in K562 cells resistant to Imatinib (K562 Ima-R), obtained as 
described in [10]. Interestingly, we observed that Imatinib inefficiency in 
increasing annexin V positivity and caspase activation in K562 Ima-R cells 
(fig.5A) was associated with the lack of ZNF224 induction and consistently 
of c-Myc reduction, at both mRNA and protein levels (fig.5B).  
On the contrary, forced expression of ZNF224 in these cells reduced c-Myc 
promoter activity (fig.5C), resulting in reduced c-Myc protein levels and a 
significative increase in cell death (fig.5D), thus indicating that ZNF224 
could contribute to overcome Imatinib resistance in CML cells. 
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Figure 4: ZNF224 mediates Imatinib transcriptional repression on c-Myc. 
(A) ChIP assay performed with an anti-ZNF224 antibody in K562 cells treated with 1 µM 
Imatinib or vehicle only (DMSO) as control for 24h. Quantitative real-time PCR analysis was 
performed using specific c-Myc primers covering the P2 region.  c-Myc unrelated region was 
used as negative control. Shown is the amount of immunoprecipitated P2 region or c-Myc 
unrelated region relative to that present in total input chromatin (% of input). Error bars indicate 
the mean value +/- SD of two independent experiments. ZNF224 and c-Myc protein levels were 
analyzed by Western blot. G3PDH was used as loading control. One representative blot out of 
two performed is shown. (B) DEL-6 WT and DEL-6 MUT promoter activity in K562 cells after 
Imatinib treatment. K562 cells were transfected with 0.2 µg of DEL-6 or DEL-6-MUT constructs 
and after 24 hours treated with 1µM Imatinib. Luciferase activity was determined 24 hours later 
and promoter activity was normalized to renilla luciferase activity. Error bars represent standard 
deviations of two independent experiments (*= p-value < 0,05; **p-value < 0,005). (C) K562 
cells stably silenced for ZNF224 (shE7) or with a control shRNA (shGFP) were exposed to 1 µM 
Imatinib or vehicle only (DMSO) for 48 hours. c-Myc mRNA levels were measured by RT-qPCR. 
Relative amounts of shGFP and shE7 treated with Imatinib were compared to shGFP and shE7 
treated with DMSO (control). Error bars represent standard deviations of two independent 
experiments. (D) ZNF224 and c-Myc protein levels were measured by Western Blot analysis. 
G3PDH was used as loading control. One representative blot out of two is presented. (E) Cell 
death was determined by annexin V staining followed by flow cytometry. Error bars represent 
standard deviations of three independent experiments (*= p-value < 0,05). 
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Figure 5: ZNF224 overexpression reduces c-Myc and induces cell death in K562 Ima-R cells.  
K562 Ima-R cells were exposed to 1 µM Imatinib or vehicle only (DMSO) as control (-) for 48 
hours. (A) Caspase activity was biochemically measured. Error bars represent standard deviations 
of two independent experiments. (B) ZNF224 and c-Myc mRNA levels were measured by RT-
qPCR. Relative amounts as compared to control are shown. Error bars represent standard 
deviations of three independent experiments. ZNF224 and c-Myc protein levels were measured 
by Western Blot analysis. ß-actin was used as loading control. One representative blot out of two 
is presented. (C) Luciferase reporter assay showing ZNF224 effect on the promoter activity of 
DEL-6 construct in K562 Ima-R cells. K562 Ima-R cells were transfected with DEL-6, together 
with 1.5µg of 3X-Flag ZNF224 or 3X-Flag empty vector as control (-). 48 hours after transfection 
promoter activity was determined by normalizing Firefly to renilla luciferase activity. Shown is 
promoter activity compared to control cells (-). Error bars represent standard deviations of two 
independent experiments. (D) K562 Ima-R cells were transfected with 1.5µg of 3X-Flag ZNF224 
or 1.5µg 3X-Flag expression plasmid as control (-). c-Myc protein levels were measured by 
Western Blot analysis. Tubulin was used as loading control. One representative blot out of two is 
presented. Cell death was determined by annexin V staining followed by flow cytometry. Error 
bars represent standard deviations of three independent experiments (** = p-value <0.005). 
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4.4 Jak2 inhibitor AG490 reduces c-Myc via ZNF224 induction in CML 
cells 
Janus Kinase 2 (Jak2) pathway plays a pivotal role in c-Myc induction by 
Bcr-Abl. Consistently, new inhibitor molecules targeting Jak2, downstream 
Bcr-Abl, have been reported as powerful tools to reduce c-Myc levels in 
CML and represent promising molecular tools to overcome Imatinib 
resistance. Therefore, since ZNF224 is implicated in c-Myc repression 
downstream Bcr-Abl in CML, we investigated ZNF224 involvement in c-
Myc transcriptional downregulation by AG490, a specific and potent 
inhibitor of Jak2. 
To investigate this issue, at first we treated K562 cells with AG490 and 
evaluated ZNF224 and c-Myc expression. As expected, AG490 induced cell 
death in K562 cells (fig.6A) and decreased c-Myc mRNA and protein levels 
(fig.6B and 6C).  Interestingly, the reduction of c-Myc was associated with 
an increase in ZNF224 expression (fig.6C), thus suggesting the involvement 
of Jak2 pathway in ZNF224 suppression. Similar results were also obtained 
in Jurl-MK1 CML cells (fig.S1). 
Subsequently, we investigated the effect of AG490 on the activity of the c-
Myc promoter constructs, DEL-6 and DEL-6 MUT in K562 cells. We 
observed that AG490 treatment, similarly to Imatinib (fig.4B), strongly 
reduced DEL-6 WT promoter activity, while exerted a lower repression on 
DEL-6 MUT (fig.6D), thus indicating that ZNF224 binding on c-Myc 
promoter is important for AG490-dependent repression of the c-Myc gene. 
Finally, to definitively demonstrate the involvement of ZNF224 in c-Myc 
repression by AG490, we analyzed the effect of AG490 on c-Myc expression 
in K562 cells knocked-down for ZNF224 (shE7) compared to control cells 
(shGFP). Interestingly, as shown in figures 6E and 6F, ZNF224 silencing 
strongly impaired AG490-mediated downregulation of c-Myc expression at 
mRNA and protein levels. 
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Taken together, these results indicate that ZNF224 is a new transcription 
factor in the Bcr-Abl/Jak2-c-Myc transcriptional pathway in CML and 
demonstrate that ZNF224 induction mediates, at least in part, AG490 
transcriptional repression on c-Myc oncogene in CML cells.  
Most interestingly, AG490 treatment of cultured peripheral mononuclear 
cells (PBMC) obtained from CML patients at diagnosis and sensitive to 
Imatinib (Fig.S2), led to an increased ZNF224 expression which was 
associated with caspase-3 cleavage (fig.7A) and cell death (fig.7B). As 
shown in fig.S3, ZNF224 protein levels in PBMC from CML patients at 
diagnosis was lower compared to PBMC from healthy donors. 
Altogether, these preliminary results are in agreement with our previous 
results, reporting lower ZNF224 mRNA levels in CML patients compared to 
healthy donor [68] and strengthened AG490 potential in increasing ZNF224 
expression and cell death in CML patients. 
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Figure 6: ZNF224 mediates AG490 transcriptional repression on c-Myc. 
(A) K562 cells were treated with 100 µM AG490 for 24h or vehicle only (DMSO) as control (-). 
Cell death was evaluated by annexin V staining followed by flow cytometry. Results represent 
the means +/- SD of two independent experiments. (B) K562 cells were treated with 100 µM 
AG490 for 10 hours or vehicle only (DMSO) as control (-). c-Myc mRNA levels were measured 
by RT-qPCR. Relative amounts as compared to control are shown. Error bars represent standard 
deviations of two independent experiments. (C) Western blot analysis of ZNF224 and c-Myc 
protein levels. G3PDH was used as loading control. One representative blot out of two performed 
is shown. (D) K562 cells were transiently transfected with 0.2µg of DEL-6 WT or DEL-6-MUT 
constructs and treated with 100µM AG490; after 10 hours, luciferase activity was determined by 
normalizing firefly to renilla luciferase activity. Error bars represent standard deviations of two 
independent experiments. (E) K562 cells stably silenced for ZNF224 (sh E7) or with a control 
shRNA (shGFP) were treated with 100µM AG490 for 10 hours. c-Myc mRNA levels were 
measured by RT-qPCR. Relative amounts as compared to shGFP and shE7 treated with vehicle 
only (DMSO) as control are shown. Error bars represent standard deviations of two independent 
experiments. (F) ZNF224 and c-Myc protein levels were measured by Western Blot analysis. 
Tubulin was used as loading control. One representative blot out of two is shown. The arrow 
indicates specific band. 
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Figure 7: Increased ZNF224 expression and cell death induction in PBMC from CML 
patients treated with AG490. 
(A) PBMC from 2 patients with CML at diagnosis (CML03, CML04) were treated with 50 µM 
AG490 for 24 hours, after which ZNF224 and cleaved caspase-3 protein levels were measured by 
Western Blot analysis. Amido-black membrane-coloration or β-actin was used as loading control. 
(B) Cell death was determined by annexin V staining followed by flow cytometry. 
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4.5 AG490 induces ZNF224 expression and cell death in Imatinib-
resistant CML cells  
Subsequently, we evaluated the effect of AG490 on cell death and 
ZNF224/c-Myc axis in Imatinib-resistant CML cells. Interestingly, we found 
that AG490 significantly induces cell death (fig.8A) and caspase activation 
(fig.8B) in K562 Ima-R and similar effects were also observed in Jurl-MK1 
Imatinib-resistant cells (Jurl-MK1 Ima-R) (fig. S4), obtained as described in 
[80]. 
Most interestingly, we observed that the induction of apoptosis in AG490 
treated K562 Ima-R cells was associated with Jak-2 inactivation, ZNF224 
induction and c-Myc reduction (fig.8C). 
Similar results were obtained in K562 Nilotinib-resistant cells (K562 Nilo-
R) [69]. Indeed, Nilotinib treatment in K562 Nilo-R did not affect ZNF224 
and c-Myc expression, while AG490 treatment was able to induce apoptosis, 
increasing ZNF224 and reducing c-Myc expression (fig. S5). 
Furthermore, coherently with the role of ZNF224 in repressing c-Myc and 
inducing cell death in Imatinib-resistant K562 cells, we demonstrated that 
ZNF224 silencing, with two different siRNA (indicated as siRNA ZNF224 
#1 and siRNA ZNF224 #2), increased c-Myc expression and significantly 
impaired AG490 induced cell death of K562 Ima-R cells (fig.8D). 
Altogether, these results demonstrate that induction of ZNF224 expression 
by AG490 may contribute to override Imatinib resistance in CML cells. 
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Figure 8: ZNF224 is involved in AG490 induced cell death of K562 Ima-R cells. 
K562 Ima-R cells were exposed to 50µM AG490 or vehicle only (DMSO) as control (-) for 48 
hours. (A) Cell death was determined by annexin V staining followed by flow cytometry. Error 
bars represent standard deviations of three independent experiments. (B) Caspase activity was 
biochemically measured. (C) ZNF224 and c-Myc mRNA levels were measured by RT-qPCR. 
Relative amounts as compared to control are shown. Error bars represent standard deviations of 
three independent experiments (** = p-value <0.005). ZNF224, c-Myc and p-JAK2 protein levels 
were measured by Western Blot analysis. ß-actin was used as loading control. One representative 
blot out of two is presented. (D) K562 Ima-R cells were silenced with two siRNA versus ZNF224 
(siRNA ZNF224 pool #1 and siRNA ZNF224 pool #2) or with a control siRNA (siLuc) and were 
exposed to 30 µM AG490 or vehicle only (DMSO) as control (-) for 30 hours. ZNF224 and c-
Myc protein levels were evaluated by Western Blot analysis. ß-actin was used as loading control. 
One representative blot out of two is presented. Cell death was determined by annexin V staining 
followed by flow cytometry. Error bars represent standard deviations of three independent 
experiments (** = p-value <0.005). 
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4.6 ZNF224 represses AXL expression in CML cells 
As previously described by Auberger et al., Imatinib resistance in K562 Ima-
R cells, is mostly due to the overexpression of AXL tyrosine kinase receptor 
[12]. Indeed, AXL knock-down restored Imatinib sensitivity of K562 Ima-R 
cells. 
By western blot analysis, we intriguingly observed that the higher expression 
of AXL was associated with a lower expression of ZNF224 in K562 Ima-R 
as compared to K562 (Fig.9A). In addition, the anti-correlation between 
ZNF224 and AXL expression levels was also observed when we compared 
K562 resistant to Nilotinib (K562 Nilo-R) or Jurl-MK1 resistant to Imatinib 
(Jurl-MK1 Ima-R) to their sensitive counterparts (Fig.9A). Resistant cells 
were obtained as described in [12] and [69]. Consistently, by real-time PCR 
we also confirmed a significative increase in AXL mRNA levels in K562 
Ima-R cells as compared to K562 (Fig. 9B). 
Interestingly, ZNF224 stable knock-down in K562 cells (shC3 and shE7) led 
to an increased expression of AXL (Fig. 10A, 10B), which was associated 
with impaired response to Imatinib (Fig. 10C). On the other hand, ZNF224 
overexpression reduced mRNA and protein expression levels of AXL (Fig. 
11A, 11B) and was associated with an increased response to Imatinib 
(Fig.11C). 
These data, coherently with ZNF224 pro-apoptotic role in CML suggested 
that the anti-apoptotic factor AXL is a new target of ZNF224 transcription 
factor.  
In consistency with the potential role of ZNF224 as a transcriptional 
repressor of AXL gene, we found a putative ZNF224 binding site on AXL 
promoter region, extending from -614 to +7 (Fig. 12A). 
In order to confirm ZNF224 transcriptional repression on AXL gene, we 
performed luciferase assays in HEK293 cells. A luciferase reporter plasmid 
48	
	
containing the AXL promoter region -614/+7 (P6-AXL) (Fig.12A) was 
introduced into HEK293 cells together with increasing amounts of the 
ZNF224 expression vector and luciferase activity was measured. We 
observed that AXL promoter activity was reduced in a dose-dependent 
manner by ZNF224 overexpression (Fig. 12B). Furthermore, we also 
confirmed that ZNF224 repressed AXL promoter activity in K562 cells (Fig. 
12C). Interestingly, ZNF224 forced expression in K562 Ima-R cells resulted 
in a reduction of AXL promoter activity (Fig.13A) and protein expression 
levels (Fig.13B), thus suggesting a potential role for ZNF224 induction in 
Imatinib re-sensitization in this context.  
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Figure 9: ZNF224 and AXL expression in TKIs sensitive and resistant CML cells 
(A) ZNF224 and AXL protein levels were measured in K562, K562 Ima-R, K562 Nilo-R, Jurl-
MK1 and Jurl-MK1 Ima-R CML cells by Western Blot analysis. ß-actin was used as loading 
control. One representative blot out of two is presented. (B) AXL mRNA levels were measured 
by RT-qPCR in K562 Ima-R cells. Relative amounts as compared to K562 cells are shown. Error 
bars represent standard deviations of two independent experiments. 
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Figure 10: ZNF224 knock-down increases AXL expression and reduces Imatinib 
responsiveness in CML cells 
(A) Western blot analysis of ZNF224 and AXL protein levels in K562 cells stably silenced for 
ZNF224 (shC3 and shE7) or with a control shRNA (shGFP). G3PDH was used as loading control. 
(B) AXL mRNA levels were measured by RT-qPCR in K562 cells stably silenced for ZNF224 
(shC3 and shE7) or with a control shRNA (shGFP). (C) K562 cells stably silenced for ZNF224 
(shC3 and shE7) or with a control shRNA (shGFP) were exposed to 1 µM Imatinib or vehicle 
only (DMSO) for 48 and 72 hours. Cell death was determined by annexin V staining followed by 
flow cytometry. Error bars represent standard deviations of three independent experiments (*= p-
value < 0,05; **= p-value < 0,005). 
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        11C 
 
 
Figure 11: ZNF224 over-expression reduces AXL expression and increases Imatinib 
responsiveness in CML cells 
K562 cells were transfected with 1,5µg of 3X-Flag ZNF224 or 1,5µg 3X-Flag empty 
vector as control (-). (A) Western blot analysis of ZNF224-Flag and AXL protein levels. 
Tubulin was used as loading control. (B) AXL mRNA levels were measured by RT-
qPCR. Relative amounts as compared to control are shown. Error bars represent standard 
deviations of two independent experiments. (C) K562 cells stably transfected with 
ZNF224-Flag or 3X-Flag empty vector (control) were treated with Imatinib 1 µM or 
vehicle only (DMSO) for 24 hours. Cell death was determined by annexin V labeling 
followed by flow cytometry. (* = p-value <0.05; ** = p-value <0.005) 
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Figure 12: ZNF224 reduces AXL expression via a transcriptional mechanism 
(A) Schematic representation of AXL promoter region and P6 constructs of the AXL promoter. 
(B)  Luciferase reporter assay showing AXL promoter activity. 0.5 µg of AXL P6 construct were 
transfected into HEK293 cells together with 0.4µg, 0.6µg, 0.8µg of 3X-Flag ZNF224 or 3X-Flag 
empty vector as control (-). 24h hours after transfection, promoter activity was determined by 
normalizing Firefly to Renilla luciferase activity. Error bars represent standard deviations of two 
independent experiments. ZNF224 overexpression was controlled by Western Blot analysis. 
G3PDH was used as loading control. One representative blot out of two performed is presented. 
(C) Luciferase reporter assay showing ZNF224 effect on the promoter activity of P6-AXL 
construct in K562 cells. K562 cells were transfected with P6-AXL together with 1µg of 3X-Flag 
ZNF224 or 1µg 3X-Flag empty vector as control (-). 48 hours after transfection promoter activity 
was determined by normalizing Firefly to renilla luciferase activity. Shown is promoter activity 
compared to control cells (-). Error bars represent standard deviations of three independent 
experiments. 
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Figure 13: ZNF224 reduces AXL expression in K562 Ima-R cells 
(A) Luciferase reporter assay showing ZNF224 effect on the promoter activity of P6-
AXL construct in K562 Ima-R cells. K562 Ima-R cells were transfected with P6-AXL, 
together with 1µg of 3X-Flag ZNF224 or 1µg 3X-Flag empty vector as control (-). 48 
hours after transfection promoter activity was determined by normalizing Firefly to 
renilla luciferase activity. Shown is promoter activity compared to control cells (-). Error 
bars represent standard deviations of two independent experiments. (B) K562 Ima-R cells 
were transfected with 1.5µg of 3X-Flag ZNF224 or 1.5µg 3X-Flag  empty vector as 
control (-). ZNF224-Flag and AXL protein levels were measured by Western Blot 
analysis. G3PDH was used as loading control. One representative blot out of two is 
presented. 
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4.7 Supplementary data 
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Figure S1: AG490 increases ZNF224 expression and induces cell death in Jurl-MK1 CML 
cells. Jurl-MK1 cells were treated with 50 µM AG490 for 48 hours or vehicle only (DMSO) as 
control (-). ZNF224 and c-Myc protein levels were measured by Western Blot analysis. ß-actin 
was used as loading control. Cell death was evaluated by annexin V staining followed by flow 
cytometry. Results represent the means +/- SD of two independent experiments. 
 
Figure S2: PBMC from CML patients are sensitive to Imatinib treatment. 
PBMC from 2 CML patients at diagnosis (CML03 and CML04) were treated with 1 µM 
Imatinib for 24 hours. Cell death was determined by annexin V staining followed by flow 
cytometry. 
 
Figure S3: Evaluation of ZNF224 protein levels in PBMC from CML patients at diagnosis 
ZNF224 expression level assessed by Western blot in peripheral blood of 6 patients with CML at 
diagnosis (CML01, CML02, CML03, CML04, CML05, CML06) and healthy donors (Healthy). 
Amido-black membrane-coloration or β-actin were used as loading control. 
 
Figure S4: AG490 induces cell death in Jurl-MK1 Ima-R cells. 
Jurl-MK1 Ima-R cells were exposed to 1 µM Imatinib or increasing concentrations of AG490 (10 
µM and 30 µM) or vehicle only (DMSO) as control (-) for 48 hours. Cell death was determined 
by annexin V staining followed by flow cytometry. Error bars represent standard deviations of 
two independent experiments.  
 
Figure S5: AG490 induces apoptosis and increases ZNF224 expression in K562 Nilo-R cells. 
K562 Nilo-R cells were exposed to 20 nM Nilotinib or increasing concentrations of AG490 (50 
µM and 100 µM) or vehicle only (DMSO) as control (-) for 48 hours. Cell death was determined 
by annexin V staining followed by flow cytometry. Error bars represent standard deviations of 
two independent experiments. Caspase activity was biochemically measured. Error bars represent 
standard deviations of two independent experiments. ZNF224 and c-Myc protein levels were 
measured by Western Blot analysis. ß-actin was used as loading control. One representative blot 
out of two is presented. 
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5. DISCUSSION 
 
The Kruppel-like zinc-finger protein ZNF224 plays a proapoptotic role in 
CML by acting as a transcriptional cofactor of the Wilms’ Tumor protein 1 
(WT1) and leading to down-regulation of antiapoptotic genes such as bag3 
and A1/Bfl1 and the up-regulation of proapoptotic genes such as VDR, Bax, 
Bak and IRF8. Moreover, we demonstrated that ZNF224 induction is 
necessary for ara-C induced apoptosis in CML [64,65,70]. 
Most recently, we demonstrated that Bcr-Abl oncoprotein, which drives the 
oncogenic transformation in CML, negatively regulates ZNF224 expression. 
By investigating the molecular mechanism involved in the Bcr-Abl-
dependent ZNF224 dowmodulation we identified WT1, whose expression is 
induced by Bcr-Abl oncogenic signaling, as a transcriptional repressor of 
ZNF224 in CML. Accordingly, Imatinib, Nilotinib and Dasatinib, by 
blocking Bcr-Abl tyrosine kinase activity, are able to restore ZNF224 
expression in CML cells [68]. Additional studies will be needed to identify 
other Bcr-Abl downstream effectors involved in ZNF224 regulation. In this 
work, we characterized a new mechanism by which ZNF224 exert its anti-
oncogenic role in CML. 
c-Myc oncogene induction by Bcr-Abl represents a necessary step for the 
oncogenic transformation of CML cells. In agreement, Imatinib treatment 
reduces c-Myc expression and hematopoietic tumoral features of CML cells. 
Coherently, we observed that ZNF224 induction by Imatinib well correlated 
with c-Myc oncogene reduction and cell death induction in K562 CML cells. 
Starting from these observations and from the identification of ZNF224 
putative binding sites on c-Myc promoter, we demonstrated that ZNF224 is 
a novel transcriptional repressor of c-Myc gene 
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Interestingly, we demonstrated ZNF224 repression on c-Myc oncogene both 
in K562 CML cells and in HEK293 cells, which lacks WT1 expression, thus 
showing that c-Myc is a direct target of ZNF224 transcriptional repression. 
However, since WT1 has been reported as a transcriptional activator of c-
Myc oncogene in CML [71] we cannot rule out also the involvement of 
ZNF224/WT1 complex in c-Myc transcriptional regulation in CML cells, as 
already observed for other apoptosis regulating genes [68]. Thus, we could 
speculate that ZNF224 downmodulates c-Myc transcription in CML cells, 
acting both as a transcriptional repressor that as a WT1 transcriptional 
cofactor. 
We also showed that ZNF224 repression on c-Myc in CML coherently 
resulted with a decreased proliferation and c-Myc proliferative network, 
leading to a decreased cyclin D1 expression, a positive c-Myc target gene 
and an increased p21 expression, a negative c-Myc target gene. 
Altogether, these data highlighted a new anti-oncogenic mechanism by 
which the transcription factor ZNF224 could reduce CML progression.  
In agreement with the pivotal role of c-Myc oncogene in sustaining Bcr-Abl 
oncogenic transformation in CML, the c-Myc reduction is a key step for 
Imatinib induced apoptosis in CML [13,23,24]. Interestingly, we further 
demonstrated that ZNF224 mediates, at least in part, Imatinib repression on 
c-Myc. Indeed, the blocking of Bcr-Abl tyrosine-kinase activity by Imatinib, 
increased ZNF224 expression and its binding on c-Myc promoter in CML 
cells, while ZNF224 depletion significantly affected Imatinib repression on 
c-Myc expression. In consistence with the key role of c-Myc reduction in 
Imatinib responsiveness and with the already described pro-apoptotic role of 
ZNF224 in CML cells, ZNF224 knockdown led to an expected impairment 
in Imatinib-induced cell death.  
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Furthermore, we observed that ZNF224 forced expression in K562 Ima-R 
cells was accompanied by c-Myc reduction and cell death induction, thus 
suggesting that the induction of ZNF224 expression could contribute to 
overcome Imatinib-resistance in CML. 
It has been previously demonstrated by Xie et al [22] that Bcr-Abl-mediated 
induction of c-Myc expression is dependent on activated Jak2 tyrosine 
kinase, that plays a key role in the stabilization of c-Myc protein and in the 
induction of c-Myc mRNA transcription in CML, although the molecular 
mechanisms of this induction have not been clarified. 
Consistently, Jak2 kinase inhibitors, such as AG490, strongly reduce c-Myc 
expression in CML cells and induce apoptosis, thus representing promising 
molecular tools to override Imatinib resistance in CML. 
Exploiting the newly discovered link between ZNF224 and c-Myc 
downstream Bcr-Abl in CML, we showed that ZNF224 expression is 
induced by AG490. Interestingly, ZNF224 induction mediated, at least in 
part, c-Myc transcriptional downmodulation by AG490. These findings 
suggest that ZNF224 downmodulation could represent one of the 
transcriptional mechanisms, still largely unexplored, by which Jak2 
upregulates c-Myc expression in CML. 
Most interestingly, we also demonstrated that AG490 is able to induce 
apoptosis in Imatinib-resistant K562 cells, at least in part, via ZNF224 
induction and consequent c-Myc repression.  
These new findings could be further corroborated by transcriptome analysis 
of K562 Ima-R cells treated with AG490 or overexpressing ZNF224, in order 
to find new molecular targets involved in apoptosis induction in Imatinib 
resistant cells. 
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Furthermore, in accordance with our recent results, reporting a good 
correlation between ZNF224 high expression at diagnosis and optimal 
Imatinib responsiveness in CML patients [68], we interestingly observed a 
lower expression of ZNF224 in different TKI-resistant cell lines, as 
compared to their sensitive counterparts.  
In the context of TKIs resistance in CML, several studies contributed to 
reveal new molecular effectors strictly linked to resistance, such as LYN, 
FYN, and AXL [10,11,12,44]. More in details, Auberger et al. demonstrated that 
AXL overexpression is involved in Imatinib resistance of K562 Ima-R cells, 
analyzed in this work [12]. 
Consistently, we detected a good anti-correlation between ZNF224 and AXL 
expression by comparing TKIs sensitive and resistant CML cell lines.  
Subsequently, we demonstrated that ZNF224 exerts a transcriptional 
repression on AXL gene in both K562 wild-type cells and K562 Ima-R cells. 
In consistence with the re-sensitization to Imatinib observed in K562 Ima-R 
cells silenced for AXL [12], our results indicate that ZNF224 suppression on 
AXL expression could be involved in this re-sensitization. Therefore, it 
could be of great interest to explore the epigenetic, transcriptional and post-
transcriptional mechanisms potentially involved in ZNF224 regulation in 
CML resistant cells, in order to induce its expression. As we previously 
demonstrated, WT1 is a transcriptional repressor of ZNF224 downstream 
Bcr-Abl/PI3K in CML [68], and it is reported to contribute to Imatinib 
resistance [72]; therefore, we cannot exclude that the deregulation of the WT1 
pathway in K562 Ima-R cells could be involved in ZNF224 downregulation. 
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Altogether, the present study revealed new potential ZNF224 regulatory 
roles in CML, paving the basis to consider ZNF224 as a new potential 
diagnostic tool for prognosis and drug resistance prediction in CML. 
Moreover, we enforced the rationale to consider ZNF224 induction as a 
pertinent option to hamper CML progression and hopefully overcome TKI-
resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61	
	
6. REFERENCES 
 
1. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. "Chronic myelogenous leukemia: 
biology and therapy". Annals of Internal Medicine. Aug 1999. 131 (3): 207–219.  
2. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia 
chromosome-positive leukemias. N Engl J Med 1998 319:990–8. 
3. Rudkin CT, Hungerford DA, Nowell PC. DNA Contents of chromosome Ph1 and 
chromosome 21 in human chronic granulocytic leukemia. Science 1964;144: 
1229–31. 
4. Shtivelman E, Lifshitz B, Gale RP, Ganaani E. Fused transcript of abl and bcr 
genes in chronic myelogenous leukaemia. Nature 1985; 315:550–4. 
5. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and 
transformation potency of Bcr-Abl oncogene products. Science 1990; 247:1079–
82. 
6. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous 
leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. 
Science 1990; 247:824–30. 
7. Besa, EC; Buehler, B; Markman, M; Sacher, RA. Krishnan, K, ed. "Chronic 
Myelogenous Leukemia Treatment & Management". Medscape Reference. 
WebMD. Retrieved 4 January 2014. 
8. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, 
Nagler A, Della Casa CM, Morra E, Abruzzese E, D'Emilio A, Stagno F, le Coutre 
P, Hurtado-Monroy R, Santini V, Martino B, Pane F, Piccin A, Giraldo P, 
Assouline S, Durosinmi MA, Leeksma O, Pogliani EM, Puttini M, Jang E, Reiffers 
J, Valsecchi MG, Kim DW. Multicenter independent assessment of outcomes in 
chronic myeloid leukemia patients treated with Imatinib. Journal of the National 
Cancer Institute. 2011.103 (7): 553–561. 
9. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, 
Melo JV. Selection and characterization of Bcr-Abl positive cell lines with 
differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms 
of resistance. Blood. 2000; 96:1070-1079. 
10. Grosso S, Puissant A, Dufies M, Colosetti P, Jacquel A, Lebrigand K, Barbry P, 
Deckert M, Cassuto JP, Mari B, Auberger P. Gene expression profiling of Imatinib 
and PD166326-resistant CML cell lines identifies Fyn as a gene associated with 
resistance to Bcr-Abl inhibitors. Mol Cancer Ther. 2009; 8:1924-1933. 
11. Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, Lippert E, Roche 
S, Mahon FX, Pasquet JM. Quantitative phosphoproteomics revealed interplay 
between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia 
cells. Blood. 2011.  118 (8):2211-21. 
12. Maeva Dufies, Arnaud Jacquel, Nathalie Belhacene, Guillaume Robert, Thomas 
Cluzeau, Frederic Luciano, Jill Patrice Cassuto, Sophie Raynaud and Patrick 
Auberger. Mechanisms of AXL overexpression and function in Imatinib-resistant 
chronic myeloid leukemia cells. Oncotarget 2011, November, Vol.2, No 11. 
62	
	
13. Albajar M, Gomez-Casares MT, Llorca J, Mauleon I, Vaque JP. Myc in chronic 
myeloid leukemia: induction of aberrant DNA synthesis and association with poor 
response to Imatinib. Mol Cancer Res 2011, 9: 564–576. 
14. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding 
activity of signal transducers and activators of transcription (STAT) proteins in 
hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996;183:811–20. 
15. Skorski T, Bellacosa A, Nieborowska Skorska M, Majewski M, Martinez R, Choi 
JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, et al. 
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-
3k/Akt-dependent pathway. EMBO J 1997;16: 6151–61. 
16. Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC. Activation of 
phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell 
Biol 1991; 11:1107–13. 
17. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the 
transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J 
Exp Med 1995; 181:307–13. 
18. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS, Jr. A 
requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes 
Dev 1998; 12:968–81. 
19. Sawyers CL, Callahan W and Witte ON. ONDominant negative Myc blocks 
transformation by ABL oncogenes. Cell 1992, 70, 901–910. 
20. Xie S, Wang Y, Liu J, Sun T and Arlinghaus R. Involvement of Jak2 tyrosine 
phosphorylation in Bcr-Abl transformation. Oncogene 2001, 20, 6188 ± 6195. 
21. Miyamoto N, Sugita K, Goi K, Inukai T, Lijima K, Tezuka T, Kojika S, Nakamura 
M, Kagami K and Nakazawa S. The JAK2 inhibitor AG490 predominantly 
abrogates the growth of human B-precursor leukemic cells with 11q23 
translocation or Philadelphia chromosome. Leukemia 2001, 15, 1758 ± 1768. 
22. Xie1, Hui Lin1, Tong Sun1 and Ralph B Arlinghaus. Jak2 is involved in c-Myc 
induction by Bcr-Abl Shanhai.Oncogene, 2002, 21(47):7137-46. 
23. Gomez-Casares MT, Garcia-Alegria E, Lopez-Jorge CE, Ferrandiz N, Blanco R, 
et al.Myc antagonizes the differentiation induced by Imatinib in chronic myeloid 
leukemia cells through downregulation of p27(KIP1.). Oncogene 2013, 32: 2239–
2246. 
24. Kawano T, Horiguchi-Yamada J, Iwase S, Akiyama M, Furukawa Y, et al. 
Depsipeptide enhances Imatinib mesylate-induced apoptosis of Bcr-Abl-positive 
cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this 
effect. Anticancer Res 2004, 24: 2705–2712. 
25. Porro A, Iraci N, Soverini S, Diolaiti D, Gherardi S, et al. c-Myc oncoprotein 
dictates transcriptional profiles of ATP-binding cassette transporter genes in 
chronic myelogenous leukemia CD34+ hematopoietic progenitor cells. Mol 
Cancer Res 9 2011. 1054–1066. 
26. Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, et al. Expression 
of the miR- 17–92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. 
Blood 2007, 109: 4399–4405. 
63	
	
27. Daksis JI1, Lu RY, Facchini LM, Marhin WW, Penn LJ. Myc induces cyclin D1 
expression in the absence of de novo protein synthesis and links mitogen-
stimulated signal transduction to the cell cycle. Oncogene. 1994. Dec;9(12):3635-
45. 
28. Gartel AL, Shchors K. Mechanisms of c-Myc-mediated transcriptional repression 
of growth arrest genes. Exp Cell Res 2003; 283: 17–21. 
29. Claassen GF, Hann SR. A role for transcriptional repression of p21CIP1 by c-Myc 
in overcoming transforming growth factor β-induced cell-cycle arrest. Proc Natl 
Acad Sci U S A 2000; 97: 9498–503. 
30. Gartel AL, Ye X, Goufman E, et al. Myc represses the p21(WAF1/CIP1) promoter 
and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A 2001; 98: 4510–
5.Abstract/FREE Full Text 
31. Mitchell KO, El-Deiry WS. Overexpression of c-Myc inhibits p21WAF1/CIP1 
expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate 
(TPA)-sensitive human cancer cells. Cell Growth Differ 1999; 10: 223–
30.Abstract/FREE Full Text 
32. Seoane J, Le HV, Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor 
influences the outcome of the p53 response to DNA damage. Nature 2002; 419: 
729–34. 
33. Wu S, Cetinkaya C, Munoz-Alonso MJ, et al. Myc represses differentiation-
induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core 
promoter. Oncogene 2003; 22: 351–60. 
34. Baldin V1, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear 
protein required for cell cycle progression in G1. Genes and Dev.1993. 7: 812-821. 
35. Hall M., Bates S., Peters G. Evidence for different modes of action of cyclin-
dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to 
cyclins. Oncogene 1995, 11:1581–1588. 
36. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 cdk-
interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 
1993, 75:805–816. 
37. Corinne Cayrol, Martine Knibiehler and Bernard Ducommun p21 binding to 
PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene, 
1998.16 (3):311-20. 
38. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic 
leukaemia by a Jak-2 inhibitor. Nature 1996; 379:645–8. 
39. Xuemei Sun, Judith E. Layton, Andrew Elefanty, and Graham J. Lieschke. 
Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and 
STI571 on Bcr-Abl–expressing cells, demonstrating synergy between AG490 and 
STI571. Blood 2001. 97.7: 2008-15  
40. Alessandra Ferrajoli, Stefan Faderl, Quin Van, David M. Harris, Waldemar Priebe, 
Hagop M. Kantarjian, Moshe Talpaz, Zeev Estrov. WP-1066, a Next-Generation 
Member of JAK-Stat Inhibitors, Induces Cell Cycle Arrest, Abrogates 
Proliferation, and Induces Apoptosis of Acute Myeloid Leukemia (AML) Cells. 
Blood  2004, 104:1169.  
64	
	
41. Edward Des Jardins and Nissim Hay. Repeated CT Elements Bound by Zinc 
Finger Proteins Control the Absolute and Relative Activities of the Two Principal 
Human c-Myc Promoters. Molecular and Cellular Biology, Sept. 1993, p. 5710-
5724.  
42. Neil M, Keith IE. Targeting a c-Myc G-quadruplex DNA with a fragment library. 
Chem Commun. 2014; 50(14): 1704-1707. 
43. Franceschin M. G-Quadruplex DNA structures and organic chemistry: more than 
one connection. Eur J Org Chem. 2009; (14): 2225-2238. 
44. Ben Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; 
Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; 
Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; 
Bokemeyer C; Helgason GV; Holyoake TL; Loges S. AXL BLOCKADE BY 
BGB324 INHIBITS Bcr-Abl TYROSINE KINASE INHIBITOR-SENSITIVE 
AND RESISTANT CHRONIC MYELOID LEUKEMIA. Clin Cancer Res.  2016. 
ISSN: 1078-0432. 
45. O’Bryan, J. P.; Frye, R. A.; Cogswell, P. C.; Neubauer, A.; Kitch, B.; Prokop, C.; 
Espinosa, R.; Le Beau, M. M.; Earp, H. S.; Liu, E. T. AXL, a transforming gene 
isolated from primary human myeloid leukemia cells, encodes a novel receptor 
tyrosine kinase. Mol. Cell. Biol. 1991, 11, 5016−5031.  
46. Graham, D. K.; DeRyckere, D.; Davies, K. D.; Earp, H. S. The TAM family: 
phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat. 
Rev. Cancer 2014, 14, 769−785. 
47. Heiring, C.; Dahlback, B.; Muller, Y. A. Ligand recognition and homophilic 
interactions in Tyro3: structural insights into the AXL/ Tyro3 receptor tyrosine 
kinase family. J. Biol. Chem. 2004, 279, 6952− 6958. 
48. Stenhoff, J.; Dahlback, B.; Hafizi, S. Vitamin K-dependent Gas6 activates ERK 
kinase and stimulates growth of cardiac fibroblasts. Biochem. Biophys. Res. 
Commun. 2004, 319, 871−878. 
49. Ruan, G. X.; Kazlauskas, A. AXL is essential for VEGF-Adependent activation of 
PI3K/Akt. EMBO J. 2012, 31, 1692−1703 
50. Vazquez-Martin, A.; Cufí, S.; Oliveras-Ferraros, C.; Torres- Garcia, V. Z.; 
Corominas-Faja, B.; Cuyàs, E.; Bonavia, R.; Visa, J.; Martin-Castillo, B.; 
Barrajón-Catalán, E.; Micol, V.; Bosch-Barrera, J.; Menendez, J. A. IGF-
1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib 
sensitizing effect of EGFR exon 19 deletion mutations. Sci. Rep. 2013, 3, 2560. 
51. Salian-Mehta, S.; Xu, M.; Wierman, M. E. AXL and MET crosstalk to promote 
gonadotropin releasing hormone (GnRH) neuronal cell migration and survival. 
Mol. Cell. Endocrinol. 2013, 374, 92−100. 
52. Mudduluru, G.; Allgayer, H. The human receptor tyrosine kinase AXL gene-
promoter characterization and regulation of constitutive expression by Sp1, Sp3 
and CpG methylation. Biosci. Rep. 2008, 28, 161−176. 
53. Mudduluru, G.; Ceppi, P.; Kumarswamy, R.; Scagliotti, G. V.; Papotti, M.; 
Allgayer, H. Regulation of AXL receptor tyrosine kinase expression by miR-34a 
and miR-199a/b in solid cancer. Oncogene 2011, 30, 2888−2899. 
65	
	
54. Lupo, A., Cesaro, E., Montano, G., Izzo, P., Costanzo, P. . ZNF224: Structure and 
role of a multifunctional KRAB-ZFP protein. Int. J. Biochem. Cell Biol. 2011, 43, 
470-473. 
55. Medugno, L., Costanzo, P., Lupo, A., Monti, M., Florio, F., Pucci, P. Izzo, P. A 
novel zinc fin- ger transcriptional repressor, ZNF224, interacts with the negative 
regulatory element (AldA-NRE) and inhibits gene expression. FEBS Lett. 2003. 
534, 93-100.  
56. Medugno, L., Florio, F., De Cegli, R., Grosso, M., Lupo, A., Costanzo, P. The 
Kruppel-like zinc finger protein ZNF224 represses aldolase A gene transcription 
by interacting with the KAP-1 corepressorprotein. Gene 2005. 359, 35-43. 
57. Cesaro, E., DeCegli, R., Medugno, L., Florio, F., Grosso, M., Lupo, A., Izzo, P., 
Costanzo, P.. The Kruppel- like zinc finger protein ZNF224 recruits the arginine 
methyl transferase PRMT5 on the transcriptional repressor complex of the aldolase 
A gene. J.Biol.Chem. 2009. 284, 32321-32330.  
58. Iacobazzi, Vito, Infantino, Vittoria; Convertini, Paolo; Vozza, Angelo; Agrimi, 
Gennaro; Palmieri, Ferdinando. Transcription of the mitochondrial citrate carrier 
gene: Identification of a silencer and its binding protein ZNF224. Biochemical and 
Biophysical Research Communications, July 2009, 386(1):186-91. 
59. E. Cesaro, G. Sodaro, G. Montano, M. Grosso, A. Lupo, P. Costanzo. The 
Complex Role of the ZNF224 Transcription Factor in Cancer. Advances in Protein 
Chemistry and Structural Biology. Elsevier Inc, 2016. ISSN 1876-162. 
http://dx.doi.org/10.1016/bs.apcsb.2016.11.003. 
60. Harada Y, Kanehira M, Fujisawa Y, Takata R, Shuin T, Miki T, et al. Cell-
permeable peptide DEPDC1-ZNF224 interferes with transcriptional repression 
and oncogenicity in bladder cancer cells. Cancer Res 2010; 70: 5829-39. 
61. Jin Gu Cho1,2, Seho Park3, Chae Hyun Lim4, Hong Sook Kim2, Seung Yong 
Song5, Tae-Young Roh4, Jong-Hyuk Sung6, Wonhee Suh7, Seok-Jin Ham4, Key-
Hwan Lim2, Sang Gyu Park2. ZNF224, Krüppel like zinc finger protein, induces 
cell growth and apoptosis-resistance by down-regulation of p21 and p53 via miR-
663. Oncotarget, 2016. 7: 31177-31190. 
62. Busiello T, Ciano M, Romano S, Sodaro G, Garofalo O, Bruzzese D, Simeone L, 
Chiurazzi F, Romano MF, Costanzo P, Cesaro E. Role of ZNF224 in cell growth 
and chemoresistance of Chronic Lymphocitic Leukemia. Human Molecular 
Genetics 2017. 26 (2): 344-353.  
63. K Vidovic, E Svensson, B Nilsson, B Thuresson, T Olofsson, A Lennartsson and 
U Gullberg. Wilms’ tumor gene 1 protein represses the expression of the tumor 
suppressor interferon regulatory factor 8 in human hematopoietic progenitors and 
in leukemic cells. Leukemia 2010, 24, 992–1000. 
64. Montano G, Ullmark T, Jernmark-Nilsson H, Sodaro G, Drott K, Costanzo P, 
Vidovic K, Gullberg U. The hematopoietic tumor suppressor interferon regulatory 
factor 8 (IRF8) is upregulated by the antimetabolite cytarabine in leukemic cells 
involving the zinc finger protein ZNF224, acting as a cofactor of the Wilms' tumor 
gene 1 (WT1) protein. Leuk Res. 2016. 40:60-7. 
66	
	
65. Montano G, Cesaro E, Fattore L, Vidovic K, Palladino C, Crescitelli R, et al. Role 
of WT1-ZNF224 interaction in the expression of apoptosis-regulating genes. Hum 
Mol Genet 2013; 22: 1771-82.   
66. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis 
by Bcr-Abl in chronic myeloid leukemia. Blood 1994; 83: 2038-2044. 
67. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter DJ. Bcr-
Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell 
death. Blood 1994; 83:1179-1187. 
68. Montano G, Vidovic K, Palladino C, Cesaro E, Sodaro G, Quintarelli C, et al. 
WT1-mediated repression of the proapoptotic transcription factor ZNF224 is 
triggered by the Bcr-Abl oncogene. Oncotarget 2015; 6: 28223-37.  
69. Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, 
Manley PW, Leroy C, Etienne G, Roche S, Pasquet JM. Evidence that resistance 
to nilotinib may be due to Bcr-Abl, Pgp, or Src kinase overexpression. Cancer 
Research 2008, vol. 68 (23) pp. 9809. 
70. Florio F, Cesaro E, Montano G, Izzo P, Miles C, Costanzo P. Biochemical and 
functional interaction between ZNF224 and ZNF255, two members of the 
Kruppel-like zinc-finger protein family and WT1 protein isoforms. Hum Mol 
Genet 2010; 19: 3544-458 56. 
71. Youqi Han, Serban San-Marina, Jian Liu and Mark D Minden. Transcriptional 
activation of c-Myc proto-oncogene by WT1 protein Oncogene 2004 23, 6933–
6941 
72. E Svensson, K Vidovic, C Lassen, J Richter, T Olofsson, T Fioretos and U 
Gullberg. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 
mediates resistance to Imatinib in human leukaemia cells. Leukemia 2007, 21, 
2485–2494. 
73. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: 
biologic functions, signaling, and potential therapeutic targeting in human cancer. 
Adv Cancer Res. 2008; 100:35-83. 
74. Linger RM, Keating AK, Earp HS, Graham DK. Taking aim at Mer and AXL 
receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin 
Ther Targets. 2010; 14:1073-1090. 
75. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, Weimer R, Wu 
Y, Pei L. An anti-AXL monoclonal antibody attenuates xenograft tumor growth 
and enhances the effect of multiple anticancer therapies. Oncogene 2010, 29:5254-
5264. 
76. Huang F, Hurlburt W, Greer A, Reeves KA, Hillerman S, Chang H, Fargnoli J, 
Graf Finckenstein F, Gottardis MM, Carboni JM. Differential mechanisms of 
acquired resistance to insulin-like growth factor-i receptor antibody therapy or to 
a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. 
Cancer Res. 2010; 70:7221-7231. 
77. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin 
AM, Gilmer TM. Novel mechanism of lapatinib resistance in HER2-positive 
breast tumor cells: activation of AXL. Cancer Res. 2009; 69:6871-6878. 
67	
	
78. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM, Chuang SE. 
Receptor tyrosine kinase AXL is induced by chemotherapy drugs and 
overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer 
Lett. 2008; 268:314-324. 
79. Y Li1, X Ye1, C Tan, J -A Hongo, J Zha, J Liu, D Kallop, M J C Ludlam and L 
Pei. AXL as a potential therapeutic target in cancer: role of AXL in tumor growth, 
metastasis and angiogenesis. Oncogene 2009 28, 3442–3455. 
80. Nina Fenouille, Alexandre Puissant, Maeva Dufies, Guillaume Robert, Arnaud 
Jacquel, Mickaël Ohanna, Marcel Deckert, Jean-Max Pasquet, François-Xavier 
Mahon, Jill-Patrice Cassuto, Sophie Raynaud, Sophie Tartare-Deckert and Patrick 
Auberger. Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates 
Imatinib Resistance in Chronic Myelogenous Leukemia Cells through 
Upregulation of Intracellular SPARC. Cancer Res., 2010. 70 (23):9659-70. 
81. Romano S, Xiao Y, Nakaya M, D'Angelillo A, Chang M, Jin J. FKBP51 employs 
both scaffold and isomerase functions to promote NF-κB activation in melanoma. 
Nucleic Acids Res 2015; 43:6983-93. 
82. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, 
Vogelstein B, Kinzler KW. Identification of c-Myc as a target of the APC pathway. 
Science 1998, 281(5382):1509-12. 
83. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, 
Vogelstein B, Kinzler KW. Identification of c-Myc as a target of the APC pathway. 
Science, 1998. 281(5382):1509-12. 
84. Herrant M, Jacquel A, Marchetti S, et al. Cleavage of Mcl-1 by caspases impaired 
its ability to counteract Bim-induced apoptosis. Oncogene 2004; 23:7863–73. 
 
 
 
 
 
 
 
 
 
 
 
 
 
68	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
69	
	
7. LIST OF PUBLICATIONS 
 
•   Role of ZNF224 in cell growth and chemoresistance of Chronic 
Lymphocitic Leukemia. Busiello T, Ciano M, Romano S, Sodaro G, 
Garofalo O, Bruzzese D, Simeone L, Chiurazzi F, Romano MF, 
Costanzo P, Cesaro E. Human Molecular Genetics Accepted for 
publication. Acceptance date: 2016-12-18. DOI: 
10.1093/hmg/ddw427 
 
•   The Complex Role of the ZNF224 Transcription Factor in Cancer. E. 
Cesaro, G. Sodaro, G. Montano, M. Grosso, A. Lupo, P. Costanzo. 
Advances in Protein Chemistry and Structural Biology December 
2016. Available online 5 December 2016 DOI: 
10.1016/bs.apcsb.2016.11.003 
 
•   The hematopoietic tumor suppressor interferon regulatory factor  
(IRF8) is upregulated by the antimetabolite cytarabine in leukemic 
cells involving the zinc finger protein ZNF224, acting as a cofactor of 
the Wilms' tumor gene 1 (WT1) protein. Montano G, Ullmark T, 
Jernmark-Nilsson H, Sodaro G, Drott K, Costanzo P, Vidovic K, 
Gullberg U. Leuk Res. 2016 Jan;40:60-7. doi: 
10.1016/j.leukres.2015.10.014. PMID: 26563595 
 
•   WT1-mediated repression of the proapoptotic transcription factor 
ZNF224 is triggered by the Bcr-Abl oncogene. Montano G, Vidovic 
K, Palladino C, Cesaro E, Sodaro G, Quintarelli C, De Angelis B, 
Errichiello S, Pane F, Izzo P, Grosso M, Gullberg U, Costanzo P. 
Oncotarget. 2015 Sep 29;6(29):28223-37. doi: 
10.18632/oncotarget.4950. PMID: 26320177 
70	
	
 
ONGOING MANUSCRIPT FOR PUBLICATION 
ZNF224 regolatory role in Chronic Myelogenous Leukemia, downstream 
Bcr/Abl. G Sodaro, G Montano, G Blasio, F Fiorentino, E Cesaro, P 
Costanzo. Expected year of publication: 2017. 
